AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17531768 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonconsensual sexual experiences reported by boys (touched against their will)
Number of subjects: 1057
Study 17531768 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonconsensual sexual experiences reported by girls (touched against their will)
Number of subjects: 1057
Study 17531768 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with nonconsensual experiences for boys (ever worked)
Number of subjects: 1057
Study 17531768 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with nonconsensual experiences for girls (ever worked)
Number of subjects: 1057
Study 17531768 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with nonconsensual experiences for boys (friend of opposite gender)
Number of subjects: 1057
Study 17531768 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with nonconsensual experiences for girls (friend of opposite gender)
Number of subjects: 1057
Study 17531768 — intervention group
Group type: EXPERIMENTAL
Intervention: Reported attempted forced physical relationship for boys (ever worked)
Number of subjects: 1057
Study 17531768 — intervention group
Group type: EXPERIMENTAL
Intervention: Reported attempted forced physical relationship for boys (friend of opposite gender)
Number of subjects: 1057
Study 17531768 — intervention group
Group type: EXPERIMENTAL
Intervention: Reported attempted forced physical relationship for girls (friend of opposite gender)
Number of subjects: 1057
Study 17531768 — intervention group
Group type: EXPERIMENTAL
Intervention: Perpetrators of nonconsensual experiences for boys
Number of subjects: 1057
Study 17531768 — intervention group
Group type: EXPERIMENTAL
Intervention: Perpetrators of nonconsensual experiences for girls
Number of subjects: 1057
Study 17531768 — intervention group
Group type: EXPERIMENTAL
Intervention: Reported forced physical relationship for boys
Number of subjects: 1057
Study 17531768 — intervention group
Group type: EXPERIMENTAL
Intervention: Reported forced physical relationship for girls
Number of subjects: 1057
Study 16956333 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic colposuspension
Number of subjects: 0
Study 16956333 — intervention group
Group type: COMPARATOR
Intervention: Open colposuspension
Number of subjects: 0
Study 15358988 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine 4 mg/day
Number of subjects: 28
Study 10730729 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam + Alfentanil
Number of subjects: 82
Study 10730729 — intervention group
Group type: COMPARATOR
Intervention: Midazolam alone
Number of subjects: 82
Study 10730729 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam + Propofol
Number of subjects: 82
Study 10730729 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam + Alfentanil + Propofol
Number of subjects: 82
Study 9013010 — intervention group
Group type: EXPERIMENTAL
Intervention: Lytic therapy followed by heparin and warfarin (group 2)
Number of subjects: 19
Study 9013010 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (heparin and warfarin) (group 1)
Number of subjects: 19
Study 1334103 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative surgery and radiation therapy
Number of subjects: 0
Study 3922338 — intervention group
Group type: EXPERIMENTAL
Intervention: Débridement alone
Number of subjects: 34
Study 3922338 — intervention group
Group type: EXPERIMENTAL
Intervention: Trifluridine (trifluorothymidine) alone
Number of subjects: 34
Study 3922338 — intervention group
Group type: EXPERIMENTAL
Intervention: Débridement combined with trifluridine
Number of subjects: 34
Study 3922338 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 34
Study 31183384 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Number of subjects: 23
Study 31183384 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 23
Study 28716351 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based curative health services provided by trained lady health workers (LHWs) including neonatal bag and mask resuscitation and oral amoxicillin for suspected infections.
Number of subjects: 499734
Study 28716351 — intervention group
Group type: COMPARATOR
Intervention: Routine care through the existing national programme (Control group).
Number of subjects: 499734
Study 28716351 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based curative health services provided by LHWs.
Number of subjects: 499734
Study 25458801 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrocaps
Number of subjects: 719
Study 25458801 — intervention group
Group type: COMPARATOR
Intervention: Gelatin sponge
Number of subjects: 719
Study 23539641 — intervention group
Group type: EXPERIMENTAL
Intervention: Orvepitant 30 mg/day
Number of subjects: 673
Study 23539641 — intervention group
Group type: EXPERIMENTAL
Intervention: Orvepitant 60 mg/day
Number of subjects: 673
Study 23539641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 673
Study 21668750 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive spinal magnetic stimulation (SMS)
Number of subjects: 20
Study 21668750 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Sham SMS)
Number of subjects: 20
Study 19697826 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic paravertebral block (TPVB) before induction of general anaesthesia
Number of subjects: 60
Study 19697826 — intervention group
Group type: COMPARATOR
Intervention: Standard opioid general anaesthesia
Number of subjects: 60
Study 19697826 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic paravertebral block (TPVB)
Number of subjects: 60
Study 17309383 — intervention group
Group type: EXPERIMENTAL
Intervention: Agaricus blazei Murill (ABM) extract 1500 mg daily for 12 weeks
Number of subjects: 72
Study 17309383 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cellulose)
Number of subjects: 72
Study 15549975 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute normovolaemic haemodilution (ANH)
Number of subjects: 28
Study 15549975 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study 21079385 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio-Hep-B
Number of subjects: 36
Study 21079385 — intervention group
Group type: COMPARATOR
Intervention: Engerix-B
Number of subjects: 36
Study 9556464 — intervention group
Group type: EXPERIMENTAL
Intervention: 325 mg of aspirin every other day
Number of subjects: 22071
Study 9556464 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selected aspirin use after 1988
Number of subjects: 22071
Study 9556464 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo) after 1988
Number of subjects: 22071
Study 7884326 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Break (DB) procedures
Number of subjects: 18
Study 7884326 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotary Break (RB) procedures
Number of subjects: 18
Study 7884326 — intervention group
Group type: EXPERIMENTAL
Intervention: Both DB and RB methods
Number of subjects: 18
Study 7884326 — intervention group
Group type: EXPERIMENTAL
Intervention: DB and RB procedures
Number of subjects: 18
Study 7884326 — intervention group
Group type: EXPERIMENTAL
Intervention: SMT procedures
Number of subjects: 18
Study 3228680 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (7 mg.kg‐1)
Number of subjects: 9
Study 3228680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 29785716 — intervention group
Group type: EXPERIMENTAL
Intervention: VE plus TAS
Number of subjects: 221
Study 29785716 — intervention group
Group type: COMPARATOR
Intervention: VE only
Number of subjects: 221
Study 28933873 — intervention group
Group type: EXPERIMENTAL
Intervention: Note-taking
Number of subjects: 0
Study 28933873 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing
Number of subjects: 0
Study 28933873 — intervention group
Group type: COMPARATOR
Intervention: Note-taking plus note-reading
Number of subjects: 0
Study 28933873 — intervention group
Group type: COMPARATOR
Intervention: Note-taking plus testing
Number of subjects: 0
Study 26311750 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflazacort (DFZ)
Number of subjects: 340
Study 26311750 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone/prednisolone (PRED)
Number of subjects: 340
Study 26311750 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily administration of DFZ
Number of subjects: 340
Study 26311750 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily PRED
Number of subjects: 340
Study 26311750 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily DFZ
Number of subjects: 340
Study 23146816 — intervention group
Group type: EXPERIMENTAL
Intervention: Tariquidar (TQD) at 4 mg/kg
Number of subjects: 15
Study 23146816 — intervention group
Group type: EXPERIMENTAL
Intervention: Tariquidar (TQD) at 6 mg/kg
Number of subjects: 15
Study 23146816 — intervention group
Group type: EXPERIMENTAL
Intervention: Tariquidar (TQD) at 8 mg/kg
Number of subjects: 15
Study 22011689 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab 10 mg/kg
Number of subjects: 120
Study 22011689 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab 20 mg/kg
Number of subjects: 120
Study 22011689 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg
Number of subjects: 120
Study 22011689 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 18438201 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic illness self-management training
Number of subjects: 415
Study 17021768 — intervention group
Group type: EXPERIMENTAL
Intervention: Efalizumab (1 mg/kg once weekly)
Number of subjects: 2719
Study 17021768 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2719
Study 17021768 — intervention group
Group type: EXPERIMENTAL
Intervention: Efalizumab (in one study with n=793)
Number of subjects: 2719
Study 17021768 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in one study with n=793)
Number of subjects: 2719
Study 17021768 — intervention group
Group type: EXPERIMENTAL
Intervention: Efalizumab (extended treatment phase)
Number of subjects: 2719
Study 17021768 — intervention group
Group type: EXPERIMENTAL
Intervention: Efalizumab (long-term treatment phase)
Number of subjects: 2719
Study 14735295 — intervention group
Group type: EXPERIMENTAL
Intervention: quetiapine 25 mg
Number of subjects: 13
Study 14735295 — intervention group
Group type: EXPERIMENTAL
Intervention: quetiapine 100 mg
Number of subjects: 13
Study 14735295 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 13
Study 11103798 — intervention group
Group type: EXPERIMENTAL
Intervention: ONYX-015 (1 x 10^10 pfu via intratumoral injection for 5 days during week 1 of each 3-week cycle)
Number of subjects: 37
Study 11103798 — intervention group
Group type: EXPERIMENTAL
Intervention: ONYX-015 (1 x 10^10 pfu twice a day for 10 days during weeks 1 and 2 of each 3-week cycle)
Number of subjects: 37
Study 11103798 — intervention group
Group type: EXPERIMENTAL
Intervention: p53 mutant tumors
Number of subjects: 37
Study 11103798 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 37
Study 9197929 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium (Se) administration at 4000 micrograms per day from 4 days before to 4 days after chemotherapy in group A.
Number of subjects: 41
Study 9197929 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium (Se) administration in group A.
Number of subjects: 41
Study 9197929 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Se administration in first cycle, Se in second cycle).
Number of subjects: 41
Study 1347223 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane and N2O
Number of subjects: 45
Study 1347223 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane and N2O
Number of subjects: 45
Study 2991832 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg of conjugated estrogen for 25 days each month
Number of subjects: 35
Study 2991832 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg of depo‐medroxyprogesterone acetate intramuscularly every three months
Number of subjects: 35
Study 29898645 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular 'battlefield' acupuncture
Number of subjects: 0
Study 29898645 — intervention group
Group type: COMPARATOR
Intervention: Control group (no acupuncture)
Number of subjects: 0
Study 27315367 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based training system
Number of subjects: 40
Study 27315367 — intervention group
Group type: COMPARATOR
Intervention: Conventional training only
Number of subjects: 40
Study 24169657 — intervention group
Group type: EXPERIMENTAL
Intervention: DISC lens (n=111)
Number of subjects: 221
Study 24169657 — intervention group
Group type: COMPARATOR
Intervention: Single vision (SV) lens (n=110)
Number of subjects: 221
Study 24373364 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (3 sessions/week, 2 in water, 1 on land), n=42
Number of subjects: 72
Study 19594988 — intervention group
Group type: EXPERIMENTAL
Intervention: Homing in on health (HIOH) illness self-management intervention
Number of subjects: 384
Study 19594988 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 384
Study 18812733 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% albumin solution (L group, n = 68)
Number of subjects: 151
Study 18812733 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% albumin (H group, n = 83)
Number of subjects: 151
Study 16815748 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole 0.125 mg
Number of subjects: 109
Study 16815748 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole 0.25 mg
Number of subjects: 109
Study 16815748 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole 0.50 mg
Number of subjects: 109
Study 12823650 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced care intervention
Number of subjects: 211
Study 12823650 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 211
Study 10972371 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (25 mg twice-weekly subcutaneous injections)
Number of subjects: 60
Study 10972371 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 9117012 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (20 mg for 2 weeks followed by 10 mg for 4 weeks)
Number of subjects: 27
Study 9117012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 9117012 — intervention group
Group type: COMPARATOR
Intervention: Comparison of treatment groups
Number of subjects: 27
Study 9117012 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 27
Study 10071548 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin (12 months treatment)
Number of subjects: 131
Study 10071548 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin (12-18 months treatment)
Number of subjects: 131
Study 10071548 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin
Number of subjects: 131
Study 3728935 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fluids (2 litres)
Number of subjects: 212
Study 3728935 — intervention group
Group type: COMPARATOR
Intervention: No intravenous fluids
Number of subjects: 212
Study 31917122 — intervention group
Group type: EXPERIMENTAL
Intervention: SOX (100 mg/m2 of oxaliplatin on day 1 and 80 mg/m2 of S-1 on days 1-14, every 21 days, 8 cycles)
Number of subjects: 955
Study 31917122 — intervention group
Group type: COMPARATOR
Intervention: UFT/LV (300 mg/m2 of UFT and 75 mg/day of LV on days 1-28, every 35 days, 5 cycles)
Number of subjects: 955
Study 31917122 — intervention group
Group type: EXPERIMENTAL
Intervention: SOX in N2b subgroup
Number of subjects: 955
Study 31917122 — intervention group
Group type: COMPARATOR
Intervention: UFT/LV in N2b subgroup
Number of subjects: 955
Study 29435790 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotically controlled ablation
Number of subjects: 50
Study 29435790 — intervention group
Group type: COMPARATOR
Intervention: Manually controlled ablation
Number of subjects: 50
Study 27842269 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Language‐Action Therapy (ILAT)
Number of subjects: 18
Study 27842269 — intervention group
Group type: COMPARATOR
Intervention: Naming Therapy
Number of subjects: 18
Study 24200249 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation therapy (shavasana with soothing background music) daily for 1 hour for 6 weeks
Number of subjects: 67
Study 24200249 — intervention group
Group type: COMPARATOR
Intervention: Control group (no relaxation techniques)
Number of subjects: 67
Study 23357775 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigecycline 100 mg (150 mg followed by 75 mg every 12 h)
Number of subjects: 67
Study 23357775 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigecycline 75 mg (200 mg followed by 100 mg every 12 h)
Number of subjects: 67
Study 23357775 — intervention group
Group type: COMPARATOR
Intervention: Imipenem/cilastatin (1 g every 8 h)
Number of subjects: 67
Study 20150324 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 4570
Study 20150324 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 4570
Study 19142480 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 105
Study 19142480 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 105
Study 16147970 — intervention group
Group type: EXPERIMENTAL
Intervention: Dornase alfa after physiotherapy/PEP
Number of subjects: 52
Study 14974909 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral oestrogen (Premarin 1.25 mg) + Norethisterone (2.5 mg)
Number of subjects: 19
Study 14974909 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal oestrogen (Estraderm 100 microg patches twice weekly) + MPA (10 mg)
Number of subjects: 19
Study 14974909 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal oestrogen (Estraderm 100 microg patches twice weekly) + Norethisterone (2.5 mg)
Number of subjects: 19
Study 14974909 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral oestrogen (Premarin 1.25 mg) + MPA (10 mg)
Number of subjects: 19
Study 14974909 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal oestrogen (Estraderm 100 microg patches twice weekly) + CA (5 mg)
Number of subjects: 19
Study 14974909 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal oestrogen (Estraderm 100 microg patches twice weekly) + Dydrogesterone (20 mg)
Number of subjects: 19
Study 14974909 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral oestrogen (Premarin 1.25 mg) + Progestogens (various types)
Number of subjects: 19
Study 14974909 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal oestrogen (Estraderm 100 microg patches twice weekly) + Progestogens (various types)
Number of subjects: 19
Study 14974909 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral oestrogen (Premarin 1.25 mg) + MPA (10 mg) and Norethisterone (2.5 mg)
Number of subjects: 19
Study 12458987 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg/d
Number of subjects: 244
Study 12458987 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (alendronate and estrogen)
Number of subjects: 244
Study 12458987 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen 0.625 mg/d
Number of subjects: 244
Study 12458987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study 10068162 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute pain (100 s)
Number of subjects: 0
Study 10068162 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonic/unilateral face pain
Number of subjects: 0
Study 10068162 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonic/bilateral face pain
Number of subjects: 0
Study 10068162 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent/bilateral face pain
Number of subjects: 0
Study 7738622 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐FU 600 mg/m2 plus FA 300 mg/m2 on days 2 to 4 with DP 75 mg orally three times daily on days 1 to 5
Number of subjects: 181
Study 7738622 — intervention group
Group type: COMPARATOR
Intervention: 5‐FU 600 mg/m2 plus FA 300 mg/m2 on days 2 to 4 without DP
Number of subjects: 181
Study 1914056 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ml 0.5% bupivacaine with epinephrine 5 micrograms.ml‐1 (bupivacaine group, n = 10)
Number of subjects: 20
Study 1914056 — intervention group
Group type: COMPARATOR
Intervention: 20 ml preservative-free saline (placebo group, n = 10)
Number of subjects: 20
Study 7267679 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg LM 5008
Number of subjects: 15
Study 7267679 — intervention group
Group type: COMPARATOR
Intervention: 1 mg atropine
Number of subjects: 15
Study 7267679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 6428290 — intervention group
Group type: EXPERIMENTAL
Intervention: L-thyroxine therapy
Number of subjects: 33
Study 6428290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 29116394 — intervention group
Group type: EXPERIMENTAL
Intervention: ERAS protocol
Number of subjects: 27
Study 29116394 — intervention group
Group type: COMPARATOR
Intervention: Standard Protocol (SP)
Number of subjects: 27
Study 26746371 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 8099
Study 24720558 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine OSA with AHIS:AHINS ratio ≥4:1 and AHINS <10 events/hour
Number of subjects: 75
Study 24720558 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine OSA definitions
Number of subjects: 75
Study 24720558 — intervention group
Group type: EXPERIMENTAL
Intervention: AHINS <10 events/hour
Number of subjects: 75
Study 24720558 — intervention group
Group type: EXPERIMENTAL
Intervention: Males with supine OSA
Number of subjects: 75
Study 23535791 — intervention group
Group type: EXPERIMENTAL
Intervention: NEurocognitive Joyful Attentive Training Intervention (NEJATI) in 12 sessions
Number of subjects: 30
Study 23535791 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study 20542844 — intervention group
Group type: EXPERIMENTAL
Intervention: ATV/RTV + ABC/3TC
Number of subjects: 515
Study 18386544 — intervention group
Group type: COMPARATOR
Intervention: Single-surface intensive phototherapy (SsIPT)
Number of subjects: 60
Study 18386544 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-surface intensive phototherapy (DsIPT)
Number of subjects: 60